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Abstract
Background: Envelope (E) glycoprotein E2 of the hepatitis C virus (HCV) mediates binding of the
virus to target cell receptors. Nevertheless, the precise role of E1 in viral entry remains elusive.
Methods: To understand the involvement of the fusion peptide-like domain positioned at residues
264 to 290 within envelope glycoprotein E1 in HCV infection, mutants with Ala and Asn
substitutions for residues conserved between HCV and E proteins of flaviviruses or the fusion
proteins of paramyxoviruses were constructed by site-directed mutagenesis and their effects on
membrane fusion and viral infectivity were examined.
Results: None of these mutations affected the synthesis or cell surface expression of envelope
proteins, nor did they alter the formation of a non-covalent E1-E2 heterodimer or E2 binding to
the large extracellular loop of CD81. The Cys residues located at positions 272 and 281 were
unlikely involved in intra- or intermolecular disulfide bond formation. With the exception of the
G267A mutant, which showed increased cell fusion, other mutants displayed reduced or marginally
inhibited cell fusion capacities compared to the wild-type (WT) E1E2. The G267A mutant was also
an exception in human immunodeficiency virus type 1 (HIV-1)/HCV E1E2 pseudotyping analyses, in
that it showed higher one-cycle infectivity; all other mutants exhibited greatly or partially reduced
viral entry versus the WT pseudotype. All but the G278A and D279N mutants showed a WT-like
profile of E1E2 incorporation into HIV-1 particles. Since C272A, C281A, G282A, and G288A
pseudotypes bound to Huh7 cells as effectively as did the WT pseudotype, the reduced infectivity
of these pseudotypes was due to their ability to inhibit cell fusion.
Conclusion: Our results indicate that specific residues, but not the structure, of this fusion
peptide-like domain are required for mediating cell fusion and viral entry.
Background
The hepatitis C virus (HCV) is an enveloped, positive-
stranded RNA virus classified in the Hepacivirus genus of
the family Flaviviridae with a genome of 9.6 kb. More
than six distinct genotypes exist, with genotypes 1a and 1b
being the most prevalent worldwide. The viral genome is
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translated in host cells into a ~3000-amino acid (aa)-long
polyprotein, which is cleaved co-translationally and post-
translationally by both host signal peptidases and viral
proteases to generate several distinct polypeptides, includ-
ing three structural proteins located at the N-terminal
region of the polyprotein, i.e., the core protein and two
envelope (E) glycoproteins (E1, polyprotein residues 192
to 383; and E2, residues 384 to 746), the p7 protein, and
six nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A,
and NS5B). E1 and E2 form a non-covalent heterodimer
[1] and are heavily N-linked glycosylated type I integral
transmembrane proteins, with an N-terminal ectodomain
and a C-terminal hydrophobic anchor domains (reviewed
in [2,3]). E1 and E2 associate to form two types of com-
plexes: (i) heterodimers stabilized by non-covalent
bonds, which probably represent the prebudding and
functional form of the viral envelope; and (ii) high-
molecular-mass disulfide-bonded aggregates, which may
represent misfolded proteins [4-7]. Both types of com-
plexes are retained in endoplasmic reticula (ER), the pro-
posed site for HCV assembly and budding. In addition to
anchoring to ER, the transmembrane domains of E1 and
E2 also play a role in the assembly of an E1E2 heterodimer
(reviewed in [8]). E1 and E2 physically interact with each
other to play major roles in virus binding and entry into
target cells [9-11].
To circumvent the lack of a reliable and robust in vitro sys-
tem for virus propagation, various pseudotype viruses
(HCVpp) expressing HCV E1 and E2 glycoproteins were
developed in the past as mimics to study virus-cell inter-
actions. These include vesicular stomatitis virus (VSV)
pseudotypes expressing chimeric HCV E1E2 glycoproteins
that encode the transmembrane and cytoplasmic
domains of VSV glycoprotein G [12-14] and infectious
pseudotype particles utilizing retroviral and lentiviral vec-
tors expressing HCV E1E2 proteins [15-24]. A more-
recently developed culture system based on an HCV gen-
otype 2a JFH1 RNA clone, isolated from a fulminant hep-
atitis patient, to produce an infectious virus in cell culture
(HCVcc) has tremendously facilitated our understanding
of the HCV replication cycle [25-28]. So far, a number of
cellular proteins have been identified as candidate entry
receptors (reviewed in [29]). These molecules include the
tetraspanin protein, CD81 [30,31], scavenger receptor
class B type I [32], a cellular protein that binds high-den-
sity lipoprotein, the low-density lipoprotein receptor [33],
C-type lectins dendritic cell-specific intercellular adhesion
molecule grabbing nonintegrin (DC-SIGN) and L-SIGN
[34-37], heparin sulfates [38], and the asialoglycoprotein
receptor [39]. CD81 was also shown to facilitate HCVcc
entry [25-28]. The tight junction proteins, claudin-1, -6,
and -9, were also implicated as entry cofactors in HCV
infection [40,41]. In addition, occludin was recently
shown to play a critical role in viral entry [42,43].
The entry of both HCVpp and HCVcc is mediated by E1
and E2 in a pH-dependent manner [15,21,25-27,44].
After E2 binding to receptors on the host cell surface and
receptor-mediated endocytosis, HCV enters target cells via
an acid-activated membrane fusion event, where the viral
envelope fuses with an endosomal membrane by an as yet
unidentified mechanism. This low pH-induced conforma-
tional rearrangement in HCV glycoproteins is consistent
with a membrane fusion mechanism similar to that
reported for glycoproteins of flaviviruses such as tick-
borne encephalitis virus [45,46], dengue virus [21,47],
and West Nile virus [48,49]. The E protein of flaviviruses
participates in binding to cellular receptors and interacts
with cell membranes for fusion and subsequent cell entry,
as well as in directing viral assembly and budding
(reviewed in [50]). The E protein of flaviviruses folds co-
translationally with a regulatory protein, termed the prM.
This heterodimeric interaction is important for the correct
folding and transport of the fusion protein. The prM is
then cleaved by the cellular protease, furin, at a late stage
in the secretory pathway, which is a critical regulatory step
for subsequent fusion [51,52]. In these class II fusion pro-
teins, low pH-triggered conformational changes of glyco-
proteins lead to transition from a prefusion, dimeric E
protein to a fusion-competent β-sheet trimer, in which the
fusion loop is exposed to and inserts into target endo-
somal membranes to initiate the fusion process (reviewed
in [53]).
So far, the molecular events leading to membrane fusion
and cell entry by HCV are still poorly understood. Similar
to alphaviruses and flaviviruses, the organization of HCV
E1 and E2 proteins encoded in tandem implies a similar
arrangement of a regulatory protein located N-terminal to
a fusion protein. Nevertheless, predictions of which pro-
tein (E1 or E2) acts as the HCV fusion protein remain con-
troversial. Potential structural homology between the
more C-terminally located E2 glycoprotein of HCV with
other fusion proteins from the same family as well as with
other type II fusion proteins suggests that E2 is a class II
membrane fusion protein [54,55]. On the other hand,
sequence analyses suggested that the ectodomain of E1
contains a fusion peptide-like motif, which spans residues
264 to 290, similar to the fusion peptides of paramyxovi-
ruses and flaviviruses [56]. Proteomic computational
analyses also suggested that E1 of HCV and E2 of pestivi-
ruses are truncated class II fusion proteins [57].
It is now generally thought that the concerted actions of
multiple membranotropic segments in fusion proteins are
required for the fusion process [50,58,59]. Several regions
in the ectodomain of E2, such as segments 430~449,
543~560, and 603~624 (or 603~634), were shown to
possess a membrane-perturbing ability [60,61]. In assess-
ing the peptide libraries of E1 and E2, Villalaín's groupJournal of Biomedical Science 2009, 16:89 http://www.jbiomedsci.com/content/16/1/89
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identified several membrane-active segments in E1 and
E2, suggesting that both E1 and E2 participate in the
fusion process [62]. Cosset's group recently identified six
regions in E1 and E2 with features of fusion peptides and
proposed that at least three regions, i.e., residues 270 to
284, which constitute the fusion peptide-like domain of
E1, and residues 416~450 and 600~620 in E2 play a role
in membrane fusion [63]. Nevertheless, Drummer's group
mutated hydrophobic residues in this region and found
that only the F285A mutant abolished viral entry whereas
other mutations did not or only partially inhibit viral
entry [64]. They thus suggested that E1 may not function
in an analogous fashion to other class II fusion glycopro-
teins during membrane fusion. It is therefore important to
characterize the involvement of other residues in this
fusion in the viral entry process.
In the present study, we conducted mutagenesis coupled
with a human immunodeficiency virus type 1 (HIV-1)/
HCV E1E2 pseudotype approach and a cell-based fusion
assay to address the involvement of the fusion peptide-
like domain within E1 in early steps of virus-host cell
interactions. We focused on those conserved residues
among HCV isolates and shared by the E protein of flavi-
viruses or the fusion peptide of paramyxoviruses. We
found that the severity of reduction in membrane fusion
and viral entry by these mutations paralleled the con-
served nature of these residues among HCV isolates. The
results also showed that specific residues, but not the
structure, of this fusion peptide-like motif are required for
cell fusion and viral entry.
Methods
Cells and antibodies
Human embryonic kidney 293T and human hepatocarci-
noma Huh7 cells were grown in Dulbecco's modified
Eagle medium (DMEM) (Invitrogen; Carlsbad, CA) sup-
plemented with 2 mM L-glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin, and 10% fetal bovine serum
(FBS). In particular, nonessential amino acids were also
added to the Huh7 culture medium. Mouse monoclonal
antibodies (MAbs) directed against HCV E1 (cat. #
C65198M) and E2 (cat. # C65167M) were purchased
from Biodesign (Saco, ME), and the rabbit anti-HCV E2
peptide antibody (cat. # GB10416) was from Genesis Bio-
tech (Xindian, Taipei County, Taiwan). H53 MAb was an
E2 conformation-specific MAb [6,65]. Hybridoma 183
(clone H12-5C) secretes an MAb that specifically recog-
nizes HIV-1 capsid protein p24 as previously described
[66]. Affinity-purified fluorescein isothiocyanate (FITC)-
conjugated anti-mouse and anti-rabbit immunoglobulin
G (IgG) was purchased from Kirkegaard & Perry Laborato-
ries (Gaithersburg, MD).
Construction of plasmids
To construct pcDNA3-E1E2, which expresses the E1 and
E2 proteins of the H77 strain, a polymerase chain reaction
(PCR) overlap extension method using pHCMV-E1HA
and pHCMV-E2HA [67] as the templates was performed.
The outer sense and antisense primers used were 5'-
CCCGGTACCGCCGCCGCCATGAATTCCGACCTCAT-
GGGGTAC-3' (which also encodes a Kozak sequence and
60 aa of the C-terminal core as the leader peptide for E1)
and 5'-CCTCCAGATTAGCCCTCCGCTTGGGATATGAG-
TAACATCATCCA-3', respectively. The internal sense and
antisense primers used were 5'-CTGCTATTTGCCGGCGT
CGACGCGGAAACCCACGTCACCGGGGAAGT-3' and 5'-
ACTTCCCCCGGTGACGTGGGTTTCCGCGTC-
GACGCCGGCAAATAGCAG-3', respectively. These prim-
ers encoded the junction sequence between E1 and E2.
The KpnI- and XbaI-cut DNA fragment was cloned in the
same sites in pcDNA3 (Invitrogen) to yield pcDNA3-
E1E2. To construct the E1 fusion peptide-like domain
mutants, the PCR overlap extension method using
pcDNA3-E1E2 as the template was performed. Oligonu-
cleotides 5'-CCATGTCACCAATGATTGCC-3' and 5'-CCT-
TCGCCCAGTTCCCCCACC-3' were used as the outer
sense and antisense primers, respectively. Internal paired
primers used to construct these mutants were: G267A, 5'-
GATCTGCTTGTCGGGAGCGCCACCCTCTGC-3' (sense)
and 5'-GCAGAGGGTGGCGCTCCCGACAAGCAGATC-3'
(antisense); C272A, 5'-GGGAGCGCCACCCTCGCCT-
CAGCCCTCTACGTG-3' (sense) and 5'-CACGTAGAG-
GGCTGAGGCGAGGGTGGCGCTCCC-3' (antisense);
G278A, 5'-TCAGCCCTCTACGTGGCCGACCTGTGCG-
GGTCT-3' (sense) and 5'-AGACCCGCACAGGTCG-
GCCACGTAGAGGGCTGA-3' (antisense); D279N, 5'-
CTCTACGTGGGGAACCTGTGCGGGTCTGTTTTT-3'
(sense) and 5'-AGACCCGCACAGGTTCCCCACGTAGAG-
GGCTGA-3' (antisense); C281A, 5'-TACGTGGGGGAC-
CTGGCCGGGTCTGTTTTTCTT-3' (sense) and 5'-
AAGAAAAACAGAGGCGCACAGGTCAAACACGTA-3'
(antisense); G282A, 5'-GGGGACCTGTGCGCCTCT-
GTTTTTCTTGTTGGT-3' (sense) and 5'-AAGAAAAACA-
GAGGCGCACAGGTCCCCCACGTA-3' (antisense); and
G288A, 5'-GTTTTTCTTGTTGCCCAACTGTTTACCT-
TCTCT-3' (sense) and 5'-GGTAAACAGTTGGGCAACAA-
GAAAAACAGACCC-3' (antisense). The PCR fragments
were digested with XhoI and BamHI, and then used to
replace the homologous sequence in WT pcDNA3-E1E2
to generate each of the mutant plasmids.
To construct pCAGGS-sCD81/LEL-Ig, which encoded the
large extracellular loop (LEL) of human CD81 (residues
123~201) flanked by the 25-aa-leader peptide of alkaline
phosphatase and the CH2 and CH3 domains of the human
IgG Fc receptor at the N- and C-termini, respectively, a
series of 5' sense overlapping primers of 5'-TTCTAGAC-
CACCATGCTGTTACTCTTGCTGTTACTGGG-3', 5'-Journal of Biomedical Science 2009, 16:89 http://www.jbiomedsci.com/content/16/1/89
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TTGCTGTTACTGGGCCTGAGGCTGCAGCTGTCCT-
TAGGT-3', 5'-CAGCTGTCCTTAGGTATCATCAGAACAC-
GAGCAAAACGA-3', and 5'-ACACGAGCAAAACGATTTG
TCAACAAGGACCAGATCG-3', and the 3' antisense
primer 5'-TGAATTCTTCCCGGAGAAGAGGTCATCG-3'
were used to amplify the coding sequences indicated
above in an assembled PCR using pcDNA3.1-hCD81-V5-
His-Topo [68] as the template. The XbaI- and EcoRI-
digested DNA fragment was used to replace the coding
sequence of angiotensin-converting enzyme 2 cloned in
pCAGGS-ACE2-CH2CH3-Ig [69] to generate pCAGGS-
sCD81/LEL-Ig.
Plasmid DNA transfection
For expression of HCV E1E2, 3 × 106 293T cells were
seeded into 10-cm Petri dishes and cultured for 24 h prior
to transfection. Subconfluent 293T monolayers were
transfected with 10 μg of wild-type (WT) or mutant E1E2-
expressing plasmids by a standard calcium phosphate
coprecipitation method. For the pseudotyping analyses,
293T cells were cotransfected with 10 μg each of an env-
defective, pNL4-3R-E-Luc reporter provirus [70], in which
a firefly luciferase gene replaces the nef gene, and WT or
mutant E1E2 plasmids using the calcium phosphate
coprecipitation method (for analysis of viral protein
expression) or Lipofectamine 2000 (Invitrogen) accord-
ing to the manufacturer's procedures (for generating pseu-
dovirions).
Fluorescence-activated cell sorter (FACS) analysis
To assess E1E2 expression, two sets of 293T cells (106/
dish) seeded in 6-cm Petri dishes were cultured for 24 h
and then transfected with 10 μg of WT or mutant E1E2
plasmids by the calcium phosphate coprecipitation
method. Two days after transfection, cells were detached
with phosphate-buffered saline (PBS) containing 0.05%
EDTA and washed twice with PBS containing 0.2% FBS.
Cells from one set were used to determine total E1E2
expression, and those from the other set were processed
for E1E2 cell-surface expression. For total protein expres-
sion, cells were fixed in 4% paraformaldehyde at 4°C for
30 min and permeabilized with 0.25% Triton X-100 at
4°C for 5 min. Cells were subsequently incubated with
100 μl of E1 MAb at a concentration of 10 μg/ml at 4°C
for 2 h. After three washes, cells were incubated with 100
μl of FITC-conjugated anti-mouse IgG at a 1:100 concen-
tration in PBS containing 0.2% FBS at 4°C for 1 h. Immu-
nostained cells were washed with PBS containing 0.2%
FBS, resuspended in 500 μl of PBS, and quantitated by a
FACSCaliber (Becton Dickinson Immunocytometry Sys-
tems; San Jose, CA) using the Flow Jo software (Tree Star,
Inc., Ashland, OR). For cell surface expression, cells were
successively incubated with 10 μg/ml of the E1 MAb and
FITC-conjugated anti-mouse IgG and fixed with 4% para-
formaldehyde; stained cells were then analyzed by flow
cytometry. Alternatively, transfected cells were examined
for total and cell surface expression of E2 using a rabbit
anti-E2 antibody and appropriate secondary antibody.
Soluble CD81 (sCD81) pull-down assay
Sub-confluent 293T cells grown in 10-cm Petri dishes
were transfected with 10 μg of pCAGGS-sCD81/LEL-Ig,
and cell-free culture supernatants were concentrated 100-
fold by centrifugation through Centricon 70 membranes
(Millipore; Billerica, MA) at 1000 × g at 4°C and used as
the source of sCD81. At the same time, 293T cells grown
in 10-cm dishes were transfected with 20 μg of pcDNA3,
WT, or mutant E1E2 plasmids. Two days after transfec-
tion, cells were lysed with cold PBS containing 1%
CHAPSO. Cell lysates were incubated with or without 100
μl of concentrated sCD81/LEL-Ig followed by incubation
with 50 μl of protein A-Sepharose 4B beads at 4°C for 2 h.
After washing twice with PBS containing 0.5% CHAPSO,
the co-precipitated proteins were eluted from protein A-
Sepharose beads with 50 μl of 2× Laemmli sample buffer
by heating to 95°C for 5 min, and the eluted proteins
were resolved by 10% sodium dodecylsulfate (SDS) poly-
acrylamide gel electrophoresis (PAGE) followed by West-
ern blotting with E1 and E2 MAbs, respectively.
SDS-PAGE and Western immunoblotting analysis
To determine E1E2 expression, 2 days after transfection,
cells were lysed with cold lysis buffer [PBS containing 1%
each of Nonidet P-40 and sodium deoxycholate and the
protease inhibitor cocktail (Roche, Basel, Switzerland)].
After centrifugation at 18,000 × g at 4°C for 10 min to
remove cell debris, the supernatants were subjected to
10% SDS-PAGE followed by Western blotting using E1-
and E2-specific MAbs, respectively. For incorporation of
HCV E1E2 into HIV-1 virions, 2 days after transfection,
viruses were isolated from culture supernatants by ultra-
centrifugation at 160,000 × g for 90 min at 4°C through 2
ml of a 20% sucrose cushion in a Beckman/Coulter (Full-
erton, CA) SW41 rotor as previously described [71]. Equal
volumes of cell and virion lysates were subjected to reduc-
ing SDS-PAGE followed by immunoblot analysis using
HCV E1 and E2 MAbs, and HIV-1 capsid p24 MAb 183,
respectively.
Metabolic labeling and immunoprecipitation
Two days after transfection, 293T cells expressing WT or
mutant E1E2 proteins were metabolically labeled with
[35S]methionine (NEN Life Science Products; Boston,
MA) for 30 min and chased with excess cold methionine
as described previously [72] for 4 h. At the indicated chase
times, cells were lysed with PBS containing 1% CHAPSO
and the complete protease inhibitor mixture. After stand-
ing at 4°C for 10 min, the cell lysates were cleared by cen-
trifugation at 10,000 × g at 4°C for 10 min. Equal volumes
of cell lysates were precipitated with 10 μl of anti-E2 MAbJournal of Biomedical Science 2009, 16:89 http://www.jbiomedsci.com/content/16/1/89
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H53. The antibody was prebound to a mixture containing
30 μl of protein A-Sepharose 4B (Amersham Biosciences).
After incubation at 4°C for 2 h, the immune complexes
were washed six times with RIPA buffer (10 mM Tris-HCl,
pH 7.2, containing 1% Triton X-100, 0.1% SDS, 1%
sodium deoxycholate, 5 mM EDTA, and 0.15 M NaCl)
and then boiled in 30μl of Laemmli buffer. The immuno-
precipitates were examined by nonreducing 10% SDS-
PAGE.
Production of HCVpp and viral entry assay
Culture supernatants were collected from 293T cells
cotransfected with pNL4-3R-E-Luc and HCV WT or mutant
E1E2 expression plasmids at 24, 48, and 72 h after trans-
fection, combined, filtered through 0.45-μm membrane
discs, and concentrated by centrifugation at 100,000 × g
for 2 h at 4°C in an SW28 rotor. Viral pellets were resus-
pended in DMEM containing 2.5% FBS to concentrate the
viral particles by 100-fold. Pseudovirions were normal-
ized by reverse transcriptase (RT) activity as previously
described [73]. Huh7 cells seeded in 48-well plates (2 ×
104/well) were cultured for 24 h, and then infected with
the WT or mutant pseudotypes containing 5 × 105 cpm of
RT activity in the presence of 8 μg/ml polybrene at 37°C
overnight. Each infection assay was performed in tripli-
cate wells. After removing the viral suspensions, cells were
incubated at 37°C for an additional 48 h before being
lysed with 60 μl per well luciferase cell lysis buffer
(Promega, Madison, WI). Fifty microliters of lysates was
added to 50 μl of luciferase substrate solution (Promega),
and the luciferase activity, in terms of relative light units,
was measured for 10 s in a Sirius luminometer (Berthold
Detection Systems, Pforzheim, Germany).
Cell-to-cell fusion assay
293T (5 × 105/well) and Huh7 (2 × 105/well) cells were
seeded in 6-well plates 1 day prior to the assay. As effector
cells, 293T cells were cotransfected with 2 μg of pCAG-
T7pol [74], a plasmid carrying the T7 RNA polymerase
gene under the control of the CAG promoter, and 1 μg
each of the WT and mutant E1E2 plasmids. For target
cells, Huh7 cells were transfected with 2 μg of
pT7EMCVLuc [74], which encodes the firefly luciferase
gene under control of the T7 promoter. Forty-eight hours
after transfection, 293T effector cells were detached from
the dishes by treatment with 0.05% EDTA in PBS and
resuspended in DMEM containing 10% FBS. 293T effector
cells were overlaid onto the target cells, and the cultures
were incubated for 5 h. The cocultures were bathed in PBS
at pH 5.0 for 2 min at 37°C, and then incubated with
DMEM containing 10% FBS for an additional 5 h. Each
cell fusion assay was performed in triplicate wells. Cells
were harvested, lysed, and assayed for firefly luciferase
activity.
Pseudotype binding assay
Binding of HCVpp to Huh7 cells was performed as previ-
ously reported [63]. Huh7 cells (3 × 105/well) seeded in
12-well plates were cultured for 24 h before HCVpp bind-
ing. Cells were incubated with WT or mutant HCV pseu-
dotypes containing 107  cpm of RT activity in a total
volume of 300 μl of DMEM containing 10% FBS and
0.1% of NaN3 at 37°C for 1 h. After three washes with 1
ml of PBS containing 2% FBS and 0.1% NaN3, cells were
incubated with 4 μg of rabbit anti-E2 in a total volume of
300 μl on ice for 2 h. After washing, cells were incubated
with a 1:100 concentration of FITC-conjugated anti-rabbit
IgG on ice for 1 h. After washing, cells were fixed with 300
μl of 4% paraformaldehyde on ice for 30 min, and then
analyzed by FACS. Alternatively, cells were fixed, permea-
bilized, and then stained with rabbit anti-E2 or anti-p24.
After incubation with FITC-conjugated anti-rabbit IgG,
the immunostained cells were analyzed by FACS.
Results
Construction and expression of E1 fusion peptide-like 
motifmutants
To understand the involvement of the E1 putative fusion
domain, which spans residues 264~290, in viral infection,
we characterized the effects of amino acid substitutions
for conserved residues in this region on viral infection.
This internal hydrophobic region of E1 bears similarities
to the predicted fusion peptide from E proteins of flavivi-
ruses [56]. First, two Cys residues located at positions 272
and 281 are highly conserved among HCV genotypes and
all flavivirus E protein sequences analyzed (Fig. 1, top and
middle panels), suggesting their role in disulfide bond
formation. Second, the Gly residue at 278 in E1 is highly
conserved among all genotypes, whereas Gly-267 exists in
all but genotype 2, and in the predicted fusion peptides of
all flavivirus E proteins examined (Fig. 1, top and middle
panels). Third, an Asp residue at position 279 is present in
all HCV genotypes and some of the flavivirus E sequences
(Fig. 1, top and middle panels). The presence of acidic res-
idues in the fusion peptides was also noted in some low-
pH-activated viral fusion proteins [75]. In addition, align-
ment of the E1 fusion peptide-like domain with the fusion
peptide of F proteins from paramyxoviruses also reveals
that the Gly residues between these two classes of fusion
domains are similar, i.e., Gly-278 and Gly-282 in HCV are
highly conserved with those derived from paramyxovi-
ruses, while Gly-288, which is found in some HCV geno-
types, is also found in the fusion protein of
paramyxoviruses (Fig. 1A, first and third panels).
Accordingly, substitutions were introduced at these con-
served residues, and their effects on the phenotypes of
E1E2 proteins were examined. In the first group, mutants
were constructed by Ala or Asn substitutions for the con-
served residues located in the N-terminal half of thisJournal of Biomedical Science 2009, 16:89 http://www.jbiomedsci.com/content/16/1/89
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Analysis of the HCV E1 putative fusion domain Figure 1
Analysis of the HCV E1 putative fusion domain. (A) Alignment of the E1 fusion peptide-like motif of HCV with the pre-
dicted fusion peptide sequences of the E protein of flaviviruses and fusion protein of paramyxoviruses. The E1 putative fusion 
peptide sequence derived from various HCV genotypes contains similarities to the predicted fusion peptide of flavivirus E glyc-
oproteins which are boxed. The spacing of Gly residues, as indicated by shading in the HCV putative fusion peptide, is also sim-
ilar to those within the fusion peptides of paramyxovirus F proteins. (B) Construction of E1 fusion peptide-like domain 
mutants. Construction of E1 mutants with substitutions of Ala or Asn for the residues as indicated in the fusion peptide-like 
domain was performed by a site-specific, oligonucleotide-directed PCR overlap extension method as described in "Materials 
and Methods". Dots in the sequence indicate that the amino acid in that position is identical to that of the WT sequence.Journal of Biomedical Science 2009, 16:89 http://www.jbiomedsci.com/content/16/1/89
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region, i.e., G267A, C272A, G278A, D279N, and C281A.
The first single-letter amino acid code indicates that the
residue located at that position was replaced by an Ala (A)
or Asn (N) residue, as shown by the second code letter.
Another group contained Ala substitutions for the con-
served Gly residues located in the C-terminal segment of
this region, i.e., G278A, G282A, and G288A mutants. All
of these mutants were constructed by oligonucleotide-
directed PCR overlap extension mutagenesis (Fig. 1B)
from a pcDNA3-based E1E2 expression plasmid derived
from a genotype of the 1a H77 strain [67].
To understand whether these E1 mutant proteins are nor-
mally expressed and processed, 293T cells were trans-
fected with each of the WT and mutant plasmids, and cell
lysates were subjected to SDS-PAGE followed by Western
blotting using MAbs specific for E1 and E2. All N-terminal
half mutants, i.e., G267A, C272A, G278A, D279N, and
C281A, produced comparable levels of E1 and E2 proteins
to those produced by the WT plasmid upon transfection
(Fig. 2A, compare lanes 3~7 to lane 2). Similarly, a steady-
state expression analysis also showed that similar
amounts of E1 and E2 to those produced by the WT and
G267A mutant were detected for the three C-terminal half
mutants, i.e., G278A, G282A, and G288A mutants (Fig.
2A, compare lanes 11~13 to lanes 9 and 10).
To confirm these results, 293T cells expressing WT or
mutant proteins were determined for the total E1 protein
by FACS. Mutations in the N-terminal half of this region
did not greatly affect E1 expression (Fig. 2B, left panel).
Likewise, similar amounts of E1 were also detected for C-
terminal half mutants compared to that produced by the
WT plasmid upon transfection (Fig. 2B, right panel).
We then determined whether these mutant proteins were
effectively expressed on the cell surface by flow cytometry
using an anti-E1 MAb. Similar levels of E1 protein of N-
terminal half mutants to that of the WT protein were
expressed on the cell surface (Fig. 2C, left panel). C-termi-
nal half mutants also produced comparable levels of E1
on the cell surface, as opposed to the WT protein (Fig. 2C,
right panel).
Next, the total and cell surface expressions of E2 expressed
by these mutants was examined along with the WT pro-
tein using a rabbit anti-E2 antibody. Mutations in this
region did not affect the levels of intracellular or cell sur-
face-bound E2 (Fig. 2D, left and right panels, respec-
tively). The low levels of E1 and E2 detected on the cell
surface were not unexpected since HCV E1 and E2 are pre-
dominantly retained in ER after synthesis and only small
amounts of E1 and E2 escape ER retention and are trans-
ported to the cell surface [15,18,76]. These results together
indicate that mutations in this region did not greatly affect
the synthesis of or processing into E1 and E2 proteins, nor
did they alter the cell surface expression of E1 and E2.
Characterization of the disulfide bond formation of Cys-
272 and Cys-281
To examine whether mutations at Cys-272 and Cys-281
may be involved in intra- or extramolecular disulfide
bond formation, cell lysates expressing WT or each of the
mutant proteins were subjected to reducing and non-
reducing SDS-PAGE followed by Western blotting using
E2 and E1 MAbs, respectively. As shown in Fig. 2E, substi-
tutions of Ala for Cys-272 and Cys-281, respectively, did
not affect the mobility of E1 or E2 under reducing or non-
reducing SDS-PAGE (Fig. 2E). Moreover, these two muta-
tions did not alter the migration profiles of E1 or E2, com-
pared to those of the WT protein (Fig. 2E). These
observations rule out the possibility that these two Cys
residues in E1 are involved in disulfide bond formation.
The cell-cell fusion ability of mutant proteins
Since the E1E2 proteins of all mutants were expressed on
the cell surface as effectively as were the WT proteins, we
then determined whether mutations in the E1 fusion pep-
tide-like domain affected the cell fusion ability of E1E2 by
a cell-based T7 polymerase/T7 promoter-driven luciferase
reporter gene activation assay as previously reported
[74,77]. As a control, a bath of cocultured effector and tar-
get cells at pH 7.0 did not mediate cell fusion; however,
exposure of cocultured cells to pH 5.0 induced membrane
fusion, as shown by detection of luciferase activity (Fig.
3A). In addition, 293T cells transfected with the WT E1E2
plasmid without pCAG-T7pol did not show cell fusion
either even cocultured cells were bathed at pH 5.0 (data
not shown). The G267A mutant showed a higher level of
cell fusion than did the WT protein (Fig. 3B). However,
the cell fusion abilities of the other N-terminal half
mutants were reduced to a level ranging from 18% (the
G278A mutant) to 51% (the D279N mutant) of that of
the WT protein, whereas the control without E1E2 expres-
sion showed a background level of 15% of that of the WT
E1E2 (Fig. 3B). For C-terminal half mutants, Ala substitu-
tion for Gly-288 did not greatly affect the fusion ability,
while Ala substitution for Gly-282 decreased the fusion
ability to 48% of that of the WT E1E2 (Fig. 3B). The actual
values of luciferase activities shown in the control and WT
samples from three separate analyses are also depicted in
Fig. 3C.
Assessment of binding of mutant proteins to sCD81
To study whether the reduced membrane fusion ability of
mutants was due to reduced E2-CD81 and/or E1-E2's
interaction with mutants, we first constructed a plasmid
encoding the LEL of CD81 flanked by the 25-aa leader
peptide of the secreted alkaline phosphatase and the
human immune IgG Fc receptor at its N and C termini,Journal of Biomedical Science 2009, 16:89 http://www.jbiomedsci.com/content/16/1/89
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respectively. This plasmid was transfected into 293T cells
to produce secreted sCD81/LEL. Next, cell lysates contain-
ing WT or mutant proteins were incubated with equal
amounts of concentrated sCD81/LEL followed by incuba-
tion with protein A-Sepharose beads. The precipitated
proteins were analyzed by Western blotting using E1 and
E2 MAbs, respectively. To assess the specificity of this
assay in detecting coprecipitation of E1 by sCD81/LEL
through E1-E2 interactions, E1HA, E2HA, and E1E2 were
separately expressed (Fig. 4A, top panel) and then copre-
cipitated with sCD81/LEL (Fig. 4A, bottom panel). E1 was
bound to sCD81/LEL only when coexpressed with E2 (Fig.
4A, bottom panel, lane 4). Also, the WT E1 and E2 pro-
teins coprecipitated with protein-A Sepharose beads only
when sCD81/LEL had been added to cell lysates (Fig. 4B,
lane 5). Similar amounts of E1 and E2 proteins of N-ter-
minal half mutants to those of the WT proteins were
bound to sCD81/LEL (Fig. 4B, compare lanes 6~10 to lane
5). In addition, mutations in the C-terminal half of the
fusion peptide-like motif did not greatly affect the copre-
cipitation of E1 and E2 with sCD81/LEL (Fig. 4B, compare
lanes 13~16 to lane 12). These results together indicate
that mutations in this region did not affect binding of E2
to CD81 or the E1-E2 association.
Formation of non-covalent E1-E2 heterodimeric 
complexes
To understand whether mutant E1 can form a non-cova-
lent heterodimer with E2, lysates of [35S]methionine-
labeled cells expressing envelope glycoproteins were pre-
cipitated with H53, an E2 conformation-dependent MAb.
The proteins isolated were resolved by nonreducing SDS-
PAGE. Similar levels of E2 were detected from WT and
mutant plasmid transfections (Fig. 4C), indicating that
mutations in the fusion peptide-like domain of E1 do not
affect the folding and assembly of E2. Also, comparable
levels of E1 were coprecipitated with E2 from WT and
mutant protein expressions (Fig. 4C), indicating that
these mutations neither affect the formation of a non-cov-
alent hetero-dimer with E2 nor alter the folding and
assembly of E1.
Viral entry properties of pseudotypes bearing E1 mutants
To study whether E1 fusion peptide-like domain mutants
are able to mediate viral entry into host cells, the ability of
these mutants to support an env-deficient, luciferase gene-
encoding HIV-1 reporter virus was examined. 293T cells
were cotransfected with pNL4-3R-E-Luc and each of the
WT or mutant E1E2 plasmids. Cell-free pseudotypes were
normalized by RT activity prior to challenge with Huh7
cells, and luciferase activity was measured 2 days after
infection. Except for the G267A mutant, which showed an
increased viral entry ability compared to WT E1E2, the
one-cycle virus infectivity of all N-terminal half mutants
was abrogated to below the background level, i.e., 6% of
that mediated by WT E1E2 (Fig. 5A). When the viral entry
ability of C-terminal half mutants was examined, the
G278A mutant also strikingly reduced its entry ability to
below the background level, while the G282A and G288A
mutants showed reduced trans-complementation abilities
to 9% and 40%, respectively, of that mediated by WT
E1E2 (Fig. 5A). The actual luciferase activities of pseudo-
types generation from pcDNA3 or WT E1E2 plasmid
cotransfection are shown in Fig. 5B.
Incorporation of mutant E1E2 into HIV-1-like particles
To understand the nature of reduced viral infectivity of
these mutant pseudotypes, cell and virion lysates
obtained from cells cotransfected with pNL4-3R-E-Luc and
each of the WT and mutant plasmids were analyzed by
Western blotting. In the analysis of N-terminal half
mutants, similar amounts of the Gag Pr55 precursor and
its cleaved products, p41 and p25/p24, were detected in
cells and virions of WT and mutant plasmid transfections
(Fig. 6A). In addition, similar amounts of intracellular E1
and E2 proteins were detected for all mutants compared
to those of WT proteins (Fig. 6A, left panel). With the
exception of the G278A and D279N mutants, which
showed reduced assembly of E1 and E2 into HIV-1-like
particles compared to the WT E1E2 (Fig. 6A, right panel,
compare lanes 5 and 6 to lane 2), the three G267A,
C272A, and C281A mutants showed comparable
amounts of E1 and E2 incorporation into the virus (Fig.
Expression of E1 mutants Figure 2 (see previous page)
Expression of E1 mutants. (A) Western blotting analysis. 293T cells were transfected with pcDNA3, marked as the control, 
or with each of the pcDNA3-dervied WT and mutant E1E2 plasmids. Cell lysates containing equal total proteins prepared 2 
days after transfection were subjected to reducing SDS-PAGE followed by Western blotting using E2- and E1-specific MAbs, 
respectively. (B to D) Analyses of mutant protein expression by FACS. 293T cells in two sets were transfected with pcDNA3 
(marked as the control) or with each of the WT and mutant proteins. Two days after transfection, one set of cells was 
assessed for total E1 expression (B) and the other for E1 cell surface expression (C) using an E1 MAb. In another separate 
experiment, transfected cells were assessed for the total and cell surface expressions of E2 with a rabbit anti-E2 antibody (D). 
(E) Analyses of Cys-substituted mutant proteins by reducing and nonreducing SDS-PAGE. 293T cells transfected with pcDNA3 
(marked as the control), WT, C272A, and C281A mutant plasmids were resolved by reducing or nonreducing conditions as 
indicated. The Western blots were then analyzed with E1- and E2-specific MAbs, respectively. The sizes in kDaltons of stand-
ard proteins were indicated to the right.Journal of Biomedical Science 2009, 16:89 http://www.jbiomedsci.com/content/16/1/89
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6A, right panel, compare lanes 3, 4, and 7 to lane 2). It is
likely that Gly-278 and Asp-279 may have a role in main-
taining an intact structure and/or in assembly of the E1E2
complex into HCVpp; therefore, mutations at these two
residues resulted in decreased E1 and E2 assembly into the
virus. When C-terminal half mutants were analyzed, Gag
synthesis, precursor processing, and assembly/budding
into virions were normal compared to WT E1E2 transfec-
tion (Fig. 6B). E1 and E2 proteins from all mutants were
also expressed normally in cells (Fig. 6B, left panel). The
G278A mutant again showed reduced incorporation of E1
and E2 into the HIV-1 pseudovirions (Fig. 6B, right panel,
compare lane 4 to lane 2). The E1 and E2 proteins of
G282A and G288A mutants were incorporated into pseu-
doparticles as effectively as were WT E1 and E2 proteins
(Fig. 6B, right panel, compare lanes 5 and 6 to lane 2).
Assessment of binding of HCVpp bearing respective 
mutant E1E2 proteins to Huh7 cells
To understand whether the reduced viral entry capacity of
mutant pseudotypes was due to their insufficient binding
to cell receptors, binding of HCVpp with alternative
mutant E1E2 proteins to target Huh7 cells [63] was per-
formed in the absence of permeabilization. Because
G278A and D279N mutants exhibited reduced E1 and E2
assembly into HCVpp virions, they were excluded from
the binding analysis. The WT and all mutant pseudotypes
analyzed bound to Huh7 cells at comparable levels, as
shown by flow cytometric analysis of bound pseudoviri-
ons in a representative experiment (Fig. 7A) or from three
independent analyses (Fig. 7B). This binding measured
E1E2-dependent binding to Huh7 cells since NL4-3R-E-
Luc reporter virus devoid of E1E2 not bind to Huh7 cells
(Fig. 7A and 7B). Figure 3
Membrane fusion ability of mutant proteins Figure 3
Membrane fusion ability of mutant proteins. (A) 
Fusion ability of WT E1 and E2 at neutral and acidic pHs. 
293T cells were cotransfected with pCAG-T7Pol and 
pcDNA3 (marked as the control) or the WT E1E2 plasmid as 
indicated, and Huh 7 cells were transfected with 
pT7EMCVLuc. Two days post-transfection, cells were 
detached, resuspended, and added to transfected Huh 7 cells. 
Five h after coculture, cells were treated with PBS at pH 7.0 
and pH 5.0, respectively, and 37°C for 2 min, and then incu-
bated for an additional 5 h. Cells were lysed and assayed for 
firefly luciferase activity. The mean values of luciferase activi-
ties from three separate analyses with standard deviation are 
shown. (B and C) The membrane fusion ability of mutant 
proteins. 293T cells were cotransfected with pCAG-T7Pol 
and pcDNA3 (marked as the control), WT, or mutant E1E2 
plasmids, and the membrane fusion abilities of WT and 
mutant proteins were assessed at pH 5.0 as described in (A). 
The luciferase activity was measured, and the relative fusion 
abilities of the mutants were expressed as a percentage of 
that of the WT E1E2 (B). The actual values of luciferase activ-
ities of the control and WT samples shown in (B) are 
depicted in (C). All the diagrams represent the results from 
three independent experiments (mean ± standard deviation), 
each of which was performed with triplicate samples.Journal of Biomedical Science 2009, 16:89 http://www.jbiomedsci.com/content/16/1/89
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Analysis of the CD81-binding ability of E2 and of the E1-E2 interactions in mutant proteins Figure 4
Analysis of the CD81-binding ability of E2 and of the E1-E2 interactions in mutant proteins. (A) 293T cells were 
transfected with pcDNA3 (marked as the control), pHCMV-E1HA, pHCMV-E2HA, and WT pcDNA3-E1E2 plasmids, respec-
tively. Two days after transfection, cells were lysed with buffer containing 1% CHAPSO. A portion of the cell lysates was 
directly resolved by reducing SDS-PAGE followed by Western blotting using E1 and E2 MAbs, respectively (top panel). 
Another portion of the lysates was incubated with equal volumes of concentrated sCD81-LEL followed by incubation with pro-
tein A-Sepharose beads. The precipitated proteins were resolved by reducing SDS-PAGE followed by Western blotting using 
E2 and E1 MAbs, respectively (bottom panel). (B) 293T cells were transfected with pcDNA3 (marked as the control) or with 
each of the WT and mutant E1E2 plasmids. Two days after transfection, cell lysates were incubated with or without concen-
trated sCD81-LEL followed by incubation with protein A-Sepharose beads. The isolated proteins were resolved by reducing 
SDS-PAGE followed by Western blotting using E2 and E1 MAbs, respectively. (C) Coprecipitation of E1 and E2 with a confor-
mation-dependent E2 MAb H53. 293T cells were transfected with pcDNA3 (marked as the control), WT, or mutant E1E2 plas-
mids. Transfected cells were metabolically labeled with [35S]methionine for 30 min and chased for 4 h. Cell lysates were 
successively incubated with the H53 MAb and protein-A-Sepharose beads, and the isolated proteins were subjected to nonre-
ducing SDS-PAGE followed by fluorography.Journal of Biomedical Science 2009, 16:89 http://www.jbiomedsci.com/content/16/1/89
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It was reported that murine leukemia virus vector particles
can bind to cells in the absence of Env-receptor interac-
tions in an early step of virus attachment to cells [78]. We
then examined whether the binding of WT HCVpp to
Huh7 cells can occur without the specific interaction
between E1E2 and HCV receptors. When the cell and virus
culture was left unpermeabilized, the WT pseudotype was
still bound to Huh7 cells, as evidenced by anti-E2 staining
(Fig. 7C, compare profiles 4 and 5 in the top panel). As
expected, no Gag signals were detected under this unper-
meabilized condition (Fig. 7C, profiles 1 to 3 in the top
panel). When the cell and virus culture was permeabi-
lized, binding with the WT pseudotype showed a higher
level of Gag signal than binding with the control virus
without E1E2; the latter only showed a moderate Gag sig-
nal (Fig. 7C, compare profiles 2 and 3 in the bottom
panel). Interestingly, a higher level of the E2 signal was
detected under the permeabilized condition compared to
binding under the unpermeabilized condition (Fig. 7C,
compare profiles 4 and 5 in the bottom panel). These
observations together indicate that binding of HCVpp to
Huh7 cells may involve both receptor-independent and -
dependent routes.
Discussion
How HCV E1 and E2 work in conjunction to mediate
fusion between cell and virus has been a long-standing
question. Lavillette et al. characterized envelope variants
with mutations in several membranotropic regions in E1
and E2 and found that certain mutations in the E1 fusion
peptide-like domain may affect cell fusion and viral entry
of HCV [63]. Although all four mutants they examined
displayed strikingly reduced viral entry abilities, the
Y276D and G282D mutants also showed a phenotype of
impaired E1E2 incorporation into the virus. Thus, the
decreased viral infectivity of those two mutants could not
be attributed to their reduced viral entry capacity. The
other two mutants, Y276F and G282A, exhibited inhib-
ited fusion ability as well as an impaired entry capacity,
indicating that the impaired viral entry of these two
mutants was due to their reduced fusion ability. Neverthe-
less, the role of this fusion peptide-like domain in viral
infection still remains to be determined. It is important to
characterize more mutations in this region to provide bet-
ter insights into how the E1 fusion peptide-like domain
may act during HCV entry.
In the present study, we examined the effects of Ala and
Asn substitutions for those residues conserved between
HCV and E proteins of flaviviruses or the fusion proteins
of paramyxoviruses on E1E2 properties. With the excep-
tion of the G267A mutant, all mutants showed reduced or
marginally inhibited fusion ability compared to the WT
E1E2 (Fig. 3). The decreased cell fusion ability of these
mutants cannot be explained by a defect in total expres-
sion and/or cell surface expression of these mutants (Fig.
2), or by a defect in E2 binding to CD81 or E1-E2 interac-
tion (Fig. 4). Since the CD81 binding of E2 is determined
by three discontinuous elements brought by the folding of
E2 [79,80], the comparable CD81 binding ability of E2 of
these mutants to that of the WT protein (Fig. 4B) indicates
Assessment of the viral entry ability of HCV pseudotypes Figure 5
Assessment of the viral entry ability of HCV pseudo-
types. Cell-free, env-defective NL4-3R-E-Luc reporter 
viruses produced from cotransfection with pcDNA3 
(marked as the control) or with WT or mutant E1E2 plas-
mids were normalized for RT activity prior to challenge with 
Huh7 cells. Two days after infection, cells were assayed for 
luciferase activity, and the relative viral entry ability mediated 
by mutant proteins was expressed as a percentage of that 
mediated by WT E1E2. Results from three independent 
experiments are shown as the mean ± standard deviation 
(A). The means of the actual luciferase activities of the con-
trol and WT samples with standard deviations are also 
shown in (B).Journal of Biomedical Science 2009, 16:89 http://www.jbiomedsci.com/content/16/1/89
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Incorporation of WT and mutant E proteins into HIV-1-like particles Figure 6
Incorporation of WT and mutant E proteins into HIV-1-like particles. 293T cells were cotransfected with pNL4-3R-
E-Luc and pcDNA3 (marked as the control) or with each of the WT and mutant E1E2 plasmids. Virions were isolated by sedi-
menting culture supernatants through a cushion containing 20% sucrose. Equal volumes of cell and virion lysates were analyzed 
by SDS-PAGE under reducing conditions followed by Western blotting using MAbs specific for E2, E1, and HIV-1 capsid p24, 
respectively.Journal of Biomedical Science 2009, 16:89 http://www.jbiomedsci.com/content/16/1/89
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Figure 7 (see legend on next page)Journal of Biomedical Science 2009, 16:89 http://www.jbiomedsci.com/content/16/1/89
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that these mutations in E1 do not affect the overall struc-
ture of E2. Similar amounts of WT and mutant E1 proteins
were coprecipitated by sCD81 through their association
with E2 in this analysis (Fig. 4B) also implied that mutant
E1 proteins effectively form a hetero-oligomer with E2.
Importantly, similar levels of E1 and E2 were coprecipi-
tated by an E2 conformation-dependent H53 MAb from
WT and mutant plasmid transfections under nonreducing
conditions (Fig. 4C), further indicating that mutations in
this domain neither affect the overall conformation of E2
nor alter the assembly of E1 and E2 into a non-covalent
heterodimer.
The partial loss of fusion ability of the G282A mutant
observed here was also noted by Lavillette et al. [63]. With
the exception of the G278A and D279N mutants, which
exhibited reduced E1 and E2 incorporation into HCVpp
virions, the other five mutations displayed a WT-like pat-
tern of E1E2 incorporation into HCVpp virions (Fig. 6).
Since pseudoparticles bearing each of the C272A, C281A,
G282A, and G288A mutant proteins bound target Huh7
cells as effectively as did the WT HCVpp (Fig. 7), the
impaired viral entry capacity of these four mutants (Fig. 5)
was due to their reduced fusion ability (Fig. 3).
It was suggested that receptor-independent binding plays
a crucial role during the early phase of virus attachment to
facilitate retroviral particles reaching the specific recep-
tor(s) and the subsequent entry process [78]. Although we
could not distinguish the proportion of receptor-depend-
ent and -independent routes in mediating the initial
attachment of WT and mutant pseudotypes to Huh7 cells
(Fig. 7), these analyses do show comparable binding of
WT and mutant pseudotypes to cells. Therefore, the differ-
ential viral entry examined by these mutants should not
be solely attributed to their difference in binding to host
cells, but rather to their differential fusion ability.
Interestingly, we also noted that the severity of reductions
in cell fusion and viral entry of the C272A, C281A,
G282A, and G288A mutants paralleled the conserved
nature of these residues among HCV genotypes. For
instance, the Cys-272 and Cys-281 residues are highly
conserved among the HCV and E proteins of flaviviruses
(Fig. 1A), and mutations at these two residues greatly
reduced the viral entry capacity (Fig. 5) and also inhibited
cell fusion ability (Fig. 3). Gly-288 is less conserved than
Gly-282 among HCV isolates (Fig. 1A), and a mutation at
this residue displayed a smaller inhibitory effect on mem-
brane fusion and viral entry compared to the Gly-282
mutant (Figs. 3, 5). Also, the C272A and C281A muta-
tions exhibited more-significant inhibitory effects on viral
entry than did the G282A and G288A mutants (Fig. 5).
It was shown that the fusion sequences from alphaviruses
and flaviviruses include Cys residues for specific disulfide
bridges which are essential for the folding stability of
fusion peptides [81,82]. The observations that the E1 and
E2 proteins of these two mutants did not migrated differ-
entially from WT E1 and E2 proteins on both reducing
and nonreducing gels (Fig. 2E) indicate that these two Cys
residues are not involved in intra- or intermolecular
disulfide bond formation. Therefore, the possibility that
these two Cys residues are involved in the structural deter-
minant of the fusion peptide-like domain is unlikely.
These results collectively imply that these two highly con-
served Cys residues located in this domain may directly
play a crucial role in cell fusion and virus entry.
The observation that the G267A mutant exhibited higher
viral entry ability compared to the WT proteins (Fig 5) cor-
relates with its higher cell fusion ability compared to the
WT E1E2 (Fig. 3). This characteristic of the G267A mutant
is consistent with the fact that Gly-267 is not conserved in
HCV genotype 2 (Fig. 1A). The increased cell fusion ability
of this mutant might be due to a stabilization effect of an
Ala substitution at this residue on E1's structure.
Conclusion
Our study has implications in understanding the molecu-
lar basis of how the E1 fusion peptide-like domain acts
during cell fusion and viral entry.
Target cell-binding ability of pseudotypes bearing mutant proteins Figure 7 (see previous page)
Target cell-binding ability of pseudotypes bearing mutant proteins. (A and B) Cell-free NL4-3R-E-Luc reporter 
viruses were produced from cotransfection with pcDNA3 (marked as the control) or with each of WT and mutant E1E2 plas-
mids, and normalized by RT activity prior to incubation with Huh7 cells. One h post-incubation, cells were successively incu-
bated with a rabbit anti-E2 antibody and FITC-conjugated anti-rabbit IgG, fixed with paraformaldehyde, and then analyzed by 
flow cytometry (A). The relative binding ability of mutant pseudotypes is expressed as a percentage of that of the WT pseudo-
type. Results were quantified from three individual experiments with the standard deviation shown (B). (C) Huh7 cells were 
incubated with medium, HIV-1 particles without E1E2 (marked as the control), and the WT pseudotype, respectively. Cells 
were then divided into two groups; one group of cells was separately immunostained with a rabbit anti-HIV-1 p24 or rabbit 
anti-E2 and fixed, and immunostained cells were analyzed by FACS (top panel). Another group of cells was fixed, permeabilized 
with paraformaldehyde, and immunostained with rabbit anti-p24 and anti-E2, respectively, followed by FACS analysis (bottom 
panel).Journal of Biomedical Science 2009, 16:89 http://www.jbiomedsci.com/content/16/1/89
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